Navigation Links
New Research Covers Current Trends and Future Directions of the High Performing Pharmaceutical District Sales Managers
Date:7/10/2008

CHAPEL HILL, N.C., July 10 /PRNewswire/ -- "The DMs will be the key to evolving the future sales model," a sales leader said in Best Practices, LLC's latest report. The research establishes that the District Sales Manager (DM) is the cornerstone of pharmaceutical sales force effectiveness. Continued field force success depends largely on the ability of companies to evolve their DM positions to meet the needs of the complex, fast-changing bio-pharma industry.

Best Practices, LLC initiated this research to help executives who oversee or train bio-pharmaceutical field sales staff to understand how industry pressures are accelerating sales force evolution and impacting district manager effectiveness. Executives can use the forward-looking benchmarks in this report to plan and implement changes needed to help DMs sustain high performance levels.

Report excerpt, "The High Performing Pharmaceutical District Sales Manager: Current Trends & Future Directions," is available at http://www3.best-in-class.com/rr965.htm

Sample key findings that emerged from this research are the following:

-- The DM Role Is Expected to Become a More Strategic Position -- Time & Resources Are Shifting from Tactical to Strategic Activities

-- Regional Managers Are a Source of Untapped Productivity -- Regional Managers Are the First Source of Change

The cross-industry report covers 26 leading bio-pharma companies and interviewed forty-six managers and executives. Participants included Amgen, Eli Lilly, Roche, Sanofi-Aventis, Merck, Abbott and Wyeth.

For more information, on Best Practices, LLC's research and services, contact Cameron Tew, Manager of Research and Publishing at Best Practices, LLC at (919) 767-9246 or ctew@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. New Research Shows Cadaver Tissue Fails Nearly a Quarter of the Time in Young, Athletic ACL Reconstruction Patients
2. Cool, Dry Air Blown Under Football Shoulder Pads Reduces Body Temperature and Heart Rate, New Research Finds
3. Cool, air blown under football shoulder pads reduces body temperature and heart rate, research finds
4. NOTES research activities increase with grants from Olympus medical Systems totaling $1 million
5. Researchers Gather to Address New Tools in Development for Breast Cancer Detection
6. Global Industry Analysts' Releases a Series of Medical Market Research Reports
7. UAB joins elite brain cancer research group
8. Lehigh to lead $9.6M national research center for serious behavior disorders
9. Some drugs increase risk of falling: UNC researchers
10. URMC, FDA to collaborate on national data repository for heart research
11. HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 2Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 3Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 4Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 5Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 6Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 7Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 8Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3